Xbiotech inc. (XBIT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue

12,681

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

9,674

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross margin

3,007

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

1,155

10,337

4,533

4,693

4,527

4,843

3,940

3,949

2,993

5,907

4,930

7,399

8,188

13,684

9,774

11,216

7,812

10,413

9,731

4,382

6,784

4,392

4,341

3,246

2,350

General and administrative

4,023

2,974

1,578

1,313

1,278

1,265

1,175

1,672

1,157

1,600

1,663

2,289

2,083

2,757

2,685

2,399

2,436

1,657

1,083

2,039

1,421

1,997

2,639

659

2,154

Total operating expenses

5,178

13,311

6,111

6,006

5,805

6,108

5,115

5,621

4,150

7,507

6,593

9,688

10,271

16,441

12,459

13,615

10,248

12,070

10,814

6,421

8,205

6,389

6,980

3,905

4,504

Loss from operations

-2,171

-13,311

-6,111

-6,006

-5,805

-6,108

-5,115

-5,621

-4,150

-7,507

-6,593

-9,688

-10,271

-16,441

-12,459

-13,615

-10,248

-46,540

10,814

6,421

-8,205

-6,389

-6,980

-3,905

-4,504

Other income (loss):
Interest income

1,898

185

250

51

78

129

100

107

64

68

123

114

49

49

0

0

0

-

-

-

-

-

-

-

-

Other income

-

0

0

1

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange loss

-93

-555

-289

102

-146

-136

-36

-393

17

190

265

441

-341

-6

-25

-7

-9

160

78

-323

91

36

17

-1

1

Total other income (loss)

1,805

749,630

-39

154

-59

-3

64

-286

81

258

388

555

-292

43

-25

-7

-9

181

78

-323

91

37

17

-1

1

Loss before income taxes

-366

-

-

-

-5,864

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

-352

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-14

686,495

-6,150

-5,852

-5,864

-6,111

-5,051

-5,907

-4,069

-7,249

-6,205

-9,133

-10,563

-16,398

-12,484

-13,622

-10,257

-11,889

-10,736

-6,744

-8,114

-6,352

-6,963

-3,906

-4,503

Net loss per share—basic and diluted (in dollars per share)

0.00

-

-0.15

-0.16

-0.16

-

-0.14

-0.16

-0.11

-

-0.18

-0.26

-0.32

-0.51

-0.38

-0.42

-0.32

-0.38

-0.33

-0.22

-0.29

-0.26

-0.29

-0.16

-0.19

Weighted-average number of common shares—basic and diluted (in shares)

36,169

-

41,019

37,519

35,977

-

35,819

35,819

35,447

-

35,423

35,320

33,291

32,506

32,436

32,378

32,292

32,227

32,050

31,287

27,641

25,233

24,116

23,749

23,550

Manufacturing Revenue [Member]
Revenue

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

2,166

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical Trial Service Revenue [Member]
Revenue

9,681

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

7,508

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-